SNDX — Syndax Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $1.22bn
- $1.25bn
- $172.35m
Brief: Syndax to Initiate NDA Submission of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia
U.S. RESEARCH ROUNDUP- H.B. Fuller Company, Sensient Technologies, Tyler Technologies
Syndax Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Syndax Pharmaceuticals Inc expected to post a loss of 73 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-General Motors, Estee Lauder, IMAX
U.S. STOCKS ON THE MOVE-PaxMedica, Heron, Belite Bio
U.S. STOCKS ON THE MOVE-Apple, Quince, Syndax Pharma
Syndax Pharma gains as systemic disorder therapy succeeds in late-stage study
Brief: Syndax And Incyte Announce Positive Topline Results From The Pivotal AGAVE-201 Trial Of Axatilimab In Chronic Graft-Versus-Host Disease
U.S. RESEARCH ROUNDUP-Dice Therapeutics, Mongodb, Valvoline
Brief: Syndax Pharmaceuticals Files Prospectus On Offering Up To $200 Mln Shares
U.S. RESEARCH ROUNDUP-Cleveland-Cliffs, Graftech International, Steel Dynamics
Brief: Syndax Pharma Reports First Quarter 2023 Financial Results
Syndax Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: Syndax Pharmaceuticals posts Q1 net income USD -41.126 million
Syndax Pharmaceuticals Inc expected to post a loss of 60 cents a share - Earnings Preview
Syndax Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Syndax Pharmaceuticals Inc expected to post a loss of 65 cents a share - Earnings Preview
JP Morgan optimistic on Syndax Pharma's leukemia treatment